Brief: Pasithea Therapeutics Says Positive PAS-004 Tablet Pharmacokinetic Data In Ongoing Phase 1/1B Trial In Adult NF1 Patients
21/11/2025 19:18
Nov 21 (Reuters) - Pasithea Therapeutics Corp KTTA.O: PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PAS-004 TABLET PHARMACOKINETIC (PK) DATA IN ONGOING PHASE 1/1B TRIAL IN ADULT NF1 PATIENTS PASITHEA THERAPEUTICS CORP - TABLET PK EXPOSURE INCREASES PROPORTIONALLY WITH DOSE Source text: ID:nGNX36Gr1Q Further company coverage: KTTA.O (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement